Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease.

MLA

Alrouji, Mohammed, et al. “Cyclin-Dependent Kinase 5 (CDK5) Inhibitors in Parkinson Disease.” Journal of Cellular and Molecular Medicine, vol. 28, no. 11, June 2024, p. e18412. EBSCOhost, https://doi.org/10.1111/jcmm.18412.

APA

Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alshammari, M. S., Alexiou, A., Papadakis, M., Bahaa, M. M., & Batiha, G. E.-S. (2024). Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease. Journal of Cellular and Molecular Medicine, 28(11), e18412. https://doi.org/10.1111/jcmm.18412

Chicago

Alrouji, Mohammed, Haydar M Al-Kuraishy, Ali I Al-Gareeb, Mohammed S Alshammari, Athanasios Alexiou, Marios Papadakis, Mostafa M Bahaa, and Gaber El-Saber Batiha. 2024. “Cyclin-Dependent Kinase 5 (CDK5) Inhibitors in Parkinson Disease.” Journal of Cellular and Molecular Medicine 28 (11): e18412. doi:10.1111/jcmm.18412.